147 related articles for article (PubMed ID: 38358804)
1. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma.
Jiang S; Li W; Yang J; Zhang T; Zhang Y; Xu L; Hu B; Li Z; Gao H; Huang Y; Ruan S
ACS Nano; 2024 Feb; 18(8):6445-6462. PubMed ID: 38358804
[TBL] [Abstract][Full Text] [Related]
2. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment.
Yang M; Wang B; Yin Y; Ma X; Tang L; Zhang Y; Fan Q; Yin T; Wang Y
J Control Release; 2023 Jan; 353():63-76. PubMed ID: 36402232
[TBL] [Abstract][Full Text] [Related]
3. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
5. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
[TBL] [Abstract][Full Text] [Related]
6. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
[TBL] [Abstract][Full Text] [Related]
8. Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery.
Wei X; Zhan C; Chen X; Hou J; Xie C; Lu W
Mol Pharm; 2014 Oct; 11(10):3261-8. PubMed ID: 24673510
[TBL] [Abstract][Full Text] [Related]
9. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
11. Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model.
Sandbhor P; Goda J; Mohanty B; Gera P; Yadav S; Chekuri G; Chaudhari P; Dutt S; Banerjee R
Drug Deliv Transl Res; 2023 Feb; 13(2):608-626. PubMed ID: 36245060
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulant In Situ Fibrin Gel for Post-operative Glioblastoma Treatment by Macrophage Reprogramming and Photo-Chemo-Immunotherapy.
Zhang R; Ye Y; Wu J; Gao J; Huang W; Qin H; Tian H; Han M; Zhao B; Sun Z; Chen X; Dong X; Liu K; Liu C; Tu Y; Zhao S
ACS Appl Mater Interfaces; 2023 Apr; 15(14):17627-17640. PubMed ID: 37000897
[TBL] [Abstract][Full Text] [Related]
13. Targeting glioblastoma through nano- and micro-particle-mediated immune modulation.
Poot E; Maguregui A; Brunton VG; Sieger D; Hulme AN
Bioorg Med Chem; 2022 Oct; 72():116913. PubMed ID: 36007293
[TBL] [Abstract][Full Text] [Related]
14. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
15. Elucidating tumour-associated microglia/macrophage diversity along glioblastoma progression and under ACOD1 deficiency.
Pires-Afonso Y; Muller A; Grzyb K; Oudin A; Yabo YA; Sousa C; Scafidi A; Poli A; Cosma A; Halder R; Coowar D; Golebiewska A; Skupin A; Niclou SP; Michelucci A
Mol Oncol; 2022 Sep; 16(17):3167-3191. PubMed ID: 35838338
[TBL] [Abstract][Full Text] [Related]
16. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.
Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P
J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466
[TBL] [Abstract][Full Text] [Related]
17. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
18. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
19. Application prospect of peptide-modified nano targeting drug delivery system combined with PD-1/PD-L1 based immune checkpoint blockade in glioblastoma.
Song P; Zhao X; Xiao S
Int J Pharm; 2020 Nov; 589():119865. PubMed ID: 32919004
[TBL] [Abstract][Full Text] [Related]
20. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
